Paul Fatheree
Head of Chemistry

Paul Fatheree is a medicinal chemist with more than 30 years of experience in small-molecule drug discovery. He began his career at Syntex, where he contributed to the ganciclovir prodrug program that delivered valganciclovir (Valcyte®), and was later a founding chemist at Theravance, where he helped identify telavancin (Vibativ®). Over the years, his work has spanned infectious disease, cardiovascular, GI, immunology, and ophthalmology programs, with a focus on leading projects from early hit ID through IND-enabling studies. Most recently, he led medicinal chemistry and DMPK teams at DiCE Molecules and Eli Lilly, supporting oral small-molecule immunology programs including the Phase 2 small molecule IL-17 antagonists DC-806 and DC-853. He is an inventor on more than 60 patents and has co-authored 10 peer-reviewed publications. Paul holds a B.Sc. in Chemistry from UC Santa Barbara and is based in San Francisco.